Pharmacologic modulation of neutrophil functions

Clinics in Dermatology

Volumn 18, Issue 3, 2000, Pages 369-373

  Miyachi, Yoshiki ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DAPSONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GOLD DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROLIDE; METRONIDAZOLE; NITRIC OXIDE; OXYGEN RADICAL; POTASSIUM IODIDE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SUPEROXIDE; TETRACYCLINE DERIVATIVE; THALIDOMIDE; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANTIOXIDANT ACTIVITY; BEHCET DISEASE; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; HUMAN; NECROTIZING ARTERITIS; NEUTROPHIL; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SKIN INFLAMMATION; SUBCORNEAL PUSTULAR DERMATOSIS; VASCULITIS;

ANTIOXIDANTS; COLCHICINE; DAPSONE; DERMATOLOGIC AGENTS; HUMANS; METRONIDAZOLE; NEUTROPHILS; SKIN DISEASES; SULFASALAZINE; TETRACYCLINES; THALIDOMIDE;

EID: 0034612176     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00128-5     Document Type: Review

References (43)

1. Miyachi Y. Skin diseases associated with oxidative injury. In: Fuchs J, Packer L, editors. Oxidative stress in dermatology New York: Marcel Dekker, 1993:323-31.
2. Fuchs J. Oxidative injury in dermatopathology. 1992;Springer-Verlag, Berlin.
3. Miyachi Y., Niwa Y. Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates. Br J Dermatol. 107:1982;209-214.
4. Jorrizo J.L. Behcet's disease. Arch Dermatol. 122:1986;556-558.
5. Niwa Y., Miyake S., Sakane T., et al. Autooxidative damage in Behcet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol. 49:1982;247-255.
6. Horio T., Danno K., Okamoto H., et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol. 9:1983;77-81.
7. Lang P.G. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol. 1:1979;479-492.
8. Stendahl O., Molin L., Dahlgren C. The inhibition of polymorphonuclear leukocyte cyotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest. 62:1978;214-220.
9. Webster G.F., Alexander J.C., McArthur W.P., et al. Inhibition of chemiluminescence in human neutrophils by dapsone. Br J Dermatol. 110:1984;657-663.
10. Niwa Y., Miyachi Y. Inhibitory effects of dapsone on enzymatic activities of membrane phospholipids in human blood cells. Arch Dermatol Res. 277:1985;473-477.
11. Miyachi Y., Yoshioka Y., Imamura S., et al. Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species. Gut. 28:1987;190-195.
12. Miyachi Y., Yoshioka A., Horio T., et al. Prurigo pigmentosa A possible mechanism of action of sulfonamides. Dermatologica. 172:1986;82-88.
13. Booth S.A., Moody C.E., Dahl M.V., et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 98:1992;135-140.
14. Thuong-Nguyen V., Kadunce D.P., Hendrix J.D., et al. Inhibition of neutrophil adherence to antibody by dapsone A possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 100:1993;349-355.
15. Ishikawa O., Abe M., Kubota Y., et al. Dapsone suppresses the production of tumor necrosis factor-α by lipopolysaccharide-stimulated peripheral blood mononuclear cells A possible mechanism of action on discoid lupus erythematosus. Eur J Pharmacol. 344:1998;95-98.
16. Coleman M.D., Smith J.K., Perris A.D., et al. Studies on the inhibitory effects of analogues of dapsone on neutrophil function in vitro. J Pharm Pharmacol. 49:1997;53-57.
17. Tseng S., Pak G., Washenik K., et al. Rediscovering thalidomide A review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol. 35:1996;969-979.
18. Hauschild A., Kroeger H., Mitchison N.A., et al. Thalidomide therapy of established collagen-induced arthritis not accompanied by an evident Th2 shift. Clin Exp Immunol. 108:1997;428-431.
19. Miyachi Y., Ozaki M., Uchida K., et al. Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes. Arch Dermatol Res. 274:1982;363-367.
20. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med. 173:1991;699-703.
21. Moreria A.I., Sampaio E.P., Zmuidzianas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing mRNA degradation. J Exp Med. 177:1993;1675-1680.
22. Esterly N.B., Furey N.L., Flanagan L.E., et al. The effect of antimicrobial agents on chemotaxis. J Invest Dermatol. 70:1978;51-55.
23. Miyachi Y., Yoshioka A., Imamura S., et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 86:1986;449-453.
24. Mitsuyama T., Hidaka K., Furuno T., et al. Neutrophil-induced endothelial cell damage Inhibition by a 14-membered ring macrolide through action of nitric oxide. Int Arch Allergy Immunol. 114:1997;111-115.
25. Akamatsu H., Nishijima S., Akamatsu M., et al. The effect of roxithromycin on the generation of reactive oxygen species in vitro. J Int Med Res. 24:1996;27-32.
26. Miyachi Y., Imamura S., Niwa Y. Anti-oxidant action of metronidazole A possible mechanism of action in rosacea. Br J Dermatol. 114:1986;231-234.
27. Akamatsu H., Oguchi M., Nishijima S., et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid A possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 282:1990;449-454.
28. Miyachi Y., Taniguchi S., Ozaki M., et al. Colchicine in the treatment of cutaneous manifestations of Behçet's disease. Br J Dermatol. 104:1981;67-69.
29. Niwa Y., Sakane T., Miyachi Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates - in comparison with that of colchicine and various scavengers. Biochem Pharmacol. 33:1984;2355-2360.
30. Miyachi Y., Danno K., Imamura S. Suppression of active Arthus reaction by colchicine. Br J Dermatol. 105:1981;279-283.
31. Miyachi Y., Takigawa M., Imamura S. Suppression of DNCB-induced irritant dermatitis by colchicine. Acta Derm Venereol (Stockh). 61:1981;307-311.
32. Takigawa M., Miyachi Y., Uehara M., et al. Treatment of pustulosis palmaris et plantaris with oral doses of colchicine. Arch Dermatol. 118:1982;458-460.
33. Tharp M.D. Chronic urticaria Pathophysiology and treatment approaches. J Allergy Clin Immunol. 98:1996;S320-S330.
34. Akahoshi T., Namai R., Sekiyama N., et al. Rapid induction of neutrophil apoptosis by sulfasalazine Implications of reactive oxygen species in the apoptotic process. J Leukoc Biol. 62:1997;817-826.
35. Bratt J., Palmblad J. Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by antirheumatic drugs. J Lab Clin Med. 128:1996;552-560.
36. Gadangi P., Longaker M., Naime D., et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflammed sites. J Immunol. 156:1996;1937-1941.
37. Bradley S.M., le-Gallez P., Throughton P.R., et al. The effect of sulfasalazine on neutrophil superoxide generation in rheumatoid arthritis. Br J Rheumatol. 36:1997;530-534.
38. Dwarakanath A.D., Yu L.G., Brookes C., et al. "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut. 37:1995;585-588.
39. Johnson M.L., Grimwood R.E. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 130:1994;77-81.
40. Honma K., Saga K., Onodera H., et al. Potassium ioddide inhibits neutrophil chemotaxis. Acta Derm Venereol (Stockh). 70:1990;247-249.
41. Seitz M., Dewald B., Ceska M., et al. Interleukin-8 in inflammatory rheumatic diseases Synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int. 12:1992;159-164.
42. Miyachi Y., Yoshioka A., Imamura S., et al. Anti-oxidant effects of gold compounds. Br J Dermatol. 116:1987;39-46.
43. Niwa Y., Sakane T., Miyachi Y., et al. Oxygen metabolism in phagocytes of leprotic patients; enhanced endogeneous superoxide dismutase activity and hydroxyl radical generation by clofazimine. J Clin Microbiol. 20:1984;837-842.